Organic peptides - new technologies for a bio-based

Transcription

Organic peptides - new technologies for a bio-based
Organic peptides
new technologies for a bio-based
production
Dr. Christian Schwarz, Synthesis of Peptides (SynPep)
Peptides
Chains of ≤ 100 amino acids
§  Advantages §  high potency
§  high specificity
§  low toxicity
§  novel properties
§  Disadvantages
§  manufacturing costs
§  sensitivity to proteolytic digestion
2
SynPep [email protected]
Global peptide market
§  14.1 Billion USD in 2011
§  Almost exclusively therapeutical peptides
§  Key segments
§  cancer
§  metabolic disorder
§  central nervous system
§  anti-infectives
3
Transparency Market Research, 2013
SynPep [email protected]
Market Growth
§  2010
§  67 marketed peptides
§  150 in clinical phases
§  > 400 in advanced clinical phases
Frost and Sullivan, 2010
4
SynPep [email protected]
Challenges
§  Manufacturing strategies applicable on all scales
§  Quality of peptides
§  Downstreaming processing and isolation
è Costs of goods
5
Frost and Sullivan, 2010
Lonza, 2006
SynPep [email protected]
Production strategies
Chemistry
6
Biotechnology
SynPep [email protected]
Chemical synthesis
§  Currently applied for ± 90% of peptides
§  nowadays ‘chemical peptides’
Advantages
good for short peptides
(< 30 mer peptides)
automatable and scalable
(short production times)
7
Disadvantages
expensive raw materials
challenging for larger peptides
- insertions, deletions,…
chain aggregation
yield
purification
atom economy
SynPep [email protected]
Chemical synthesis
Raw materials for 20 kg of an average 18 mer peptide
Raw Material Requirements
Amino acids
0.8 tonnes
Fine chemicals
14 tonnes
Organic solvents
430 tonnes
Water
600 tonnes
è  Rather expensive approach
8
SynPep [email protected]
Biotechnological production
§  Currently applied for < 10% of peptides
Advantages
relatively cheap
scalability
easy to perform
short production time
Disadvantages
development time and costs
isolation from expression host
‘only’ 20 natural building blocks
è  ‘organic peptides’
è  No general production
strategy available
9
SynPep [email protected]
Chemistry vs. Biotechnology
Proportion of overall costs
Raw materials
Production
Chemistry
30-40% of overall costs 60% including
puri#cation and isolation
Biotechnology
5%
95% including
puri#cation and isolation
Leong, S., Singapore, Expression Systems for Peptide Production, 2007
10
SynPep [email protected]
Biotechnological production
§  Challenges during expression
11
SynPep [email protected]
Biotechnological production
§  Strategies
§  (large tandem polymer
repeated units)
12
SynPep [email protected]
Biotechnological production
§  Strategies
§  (large tandem polymer
repeated units)
§  fusion with carrier
protein
13
SynPep [email protected]
Biotechnological production
§  Procedure
§  expression of fusion
§ 
§ 
§ 
§ 
protein
cell disruption
purification
separation of peptide
from carrier protein
purification
è 5-50 mg of peptide/l
Leong, S., Singapore, Expression Systems for Peptide Production, 2007
14
SynPep [email protected]
Biotechnological production
§  Procedure
§  expression of fusion
needless?
§ 
§ 
§ 
§ 
15
protein
cell disruption
purification
separation of peptide
from carrier protein
purification
SynPep [email protected]
Biotechnological production
§  Procedure
§  expression of fusion
needless?
§ 
§ 
§ 
§ 
16
protein
cell disruption
purification
separation of peptide
from carrier protein
purification
SynPep [email protected]
Type 1 Secretion System in E. coli
outer membrane protein
kDa
cell
ex
MW tract
m
cult arker
ure
sup
erna
tant
Gram-negative cell
120
membrane fusion protein
50
30
ABC transporter
10
è  up to 1 g/l pure protein
17
SynPep [email protected]
Proteins HlyA HlyA1 LipA SprP PlaB MBP PlbF CalB Vif IFNA8 IFNA1 IFNA16 IFNA21 IFNA2 TesA IFABP Pep-des NisA HCRF Mab42 Mab40 Fuzeon® Calcitonin (human) 18
Calcitonin (salmon) Func-on Toxin -­‐-­‐-­‐ Lipase HypotheCcal protease Phospholipase Maltose binding HypotheCcal lipase Lipase Virion infecCvity factor Interferon Interferon Interferon Interferon Interferon Esterase FaRy acid binding Func-on AnCbioCc CorCcoliberin Alzheimer‘s disease Alzheimer‘s disease HIV therapy Osteoporosis Osteoporosis SynPep MW [kDa] 110.5 23.7 64.8 62.7 49.5 41.9 35.0 33.8 22.7 19.5 19.4 19.3 19.3 19.2 18.9 15.1 MW [kDa] 6.0 4.9 4.6 4.5 4.3 3.6 3.6 Yields (mg/liter) > 100 > 900 ± 2 ± 7 ± 6 ± 4 ± 9 ± 2 ± 1 ± 1 ± 1 ± 1 ± 3 ± 3 ± 4 ± 1 Yields (mg/liter) ± 5 ± 6 ± 5 ± 3 ± 2 ± 2 [email protected]
± 1 Proteins HlyA HlyA1 LipA SprP PlaB MBP PlbF CalB Vif IFNA8 IFNA1 IFNA16 IFNA21 IFNA2 TesA IFABP Pep-des NisA HCRF Mab42 Mab40 Fuzeon® Calcitonin (human) 19
Calcitonin (salmon) Func-on Toxin -­‐-­‐-­‐ Lipase HypotheCcal protease Phospholipase Maltose binding HypotheCcal lipase Lipase Virion infecCvity factor Interferon Interferon Interferon Interferon Interferon Esterase FaRy acid binding Func-on AnCbioCc CorCcoliberin Alzheimer‘s disease Alzheimer‘s disease HIV therapy Osteoporosis Osteoporosis SynPep MW [kDa] 110.5 23.7 64.8 62.7 49.5 41.9 35.0 33.8 22.7 19.5 19.4 19.3 19.3 19.2 18.9 15.1 MW [kDa] 6.0 4.9 4.6 4.5 4.3 3.6 3.6 Yields (mg/liter) > 100 > 900 ± 2 ± 7 ± 6 ± 4 ± 9 ± 2 ± 1 ± 1 ± 1 ± 1 ± 3 ± 3 ± 4 ± 1 Yields (mg/liter) ± 5 ± 6 ± 5 ± 3 ± 2 ± 2 [email protected]
± 1 ence
carri
er pr
otein
secre
ted i
nterf
minu
eron
s car
rier
Activity of secreted interferons
refer
untr
eate
d
§  highly active interferons
§  formation of disul#de bonds
20
SynPep [email protected]
General Secretion System for E. coli
§  Advantages
§  good yields for all expressed polypeptides
in batch cultures
§  high initial purity for simplified downstreaming
§  formation of disulfide bonds
§  high activity of various proteins shown
✓
✓
✓
✓
è  ‘organic peptides’
21
SynPep [email protected]
General Secretion System for E. coli
§  Road map
§  up-scaling to increase yields
§  cost-efficient separation of proteins/peptides from carrier protein
è Alternative route to organic peptides?
22
SynPep [email protected]
Alternative route to organic peptides?
§  Production of 18 mer peptide
≈ 300 – 400 mg/l cell culture!
23
SynPep [email protected]
Alternative route to organic peptides?
è  one-step puri#cation for ≥ 95% purity
24
SynPep [email protected]
Alternative route to organic peptides?
Raw Material Requirements for 20 kg of:
18 mer
18 mer
Chemical Synthesis
Alternative route*
Amino acids
0.8 tonnes
---
Fine chemicals
14 tonnes
0.1 tonnes
Bu&er compounds
---
11 tonnes
Organic solvents
430 tonnes
34 tonnes
Water
600 tonnes
292 tonnes
* calculated values based on the production of 50 mg of 18 mer
peptide, no scaling e&ects considered. 25
SynPep [email protected]
Alternative route to organic peptides!
§  Advantages
§  high yields (hundreds of mgs/l)
§  one-step purification
§  scalabel process
§  cost-efficient separation of carrier protein
✓
✓
✓
✓
è  ‘organic peptides’
26
SynPep [email protected]
Bio-based technologies of SynPep
Organic peptides with the:
1. Type 1 Secretion System
§  production of proteins (and peptides)
§  high initial purity
§  high activity
2. Alternative route
§  several hundred mgs of peptides per liter
§  cost-effective production
27
SynPep [email protected]
Acknowledgements
Prof. Dr.
K.-E. Jaeger
28
SynPep [email protected]
Our team
Dr. C. Schwarz
Dr. T. Schwarz
Prof. Dr.
Dr. S. Smits
L. Schmitt
Questions?
[email protected]
29
SynPep [email protected]